![[시그널] ‘Daeeo’ passed SK Bioscience screening… Listed in March](https://newsimg.sedaily.com/2021/02/04/22IEHYKXL0_6.jpg "[시그널] ‘Daeeo’ passed SK Bioscience screening… Listed in March")
Stock report submission during this month…March demand forecast observation
Corona 19 vaccine corporate value’mugwort’…enough trillion units of competition
viewer
SK Bioscience has crossed the last gateway for listing in March. It has passed the exchange listing screening, leaving only the public offering. With the production of a novel coronavirus infection (Corona 19) vaccine, the value of the company has soared and liquidity in the public offering market is overflowing.
The Korea Exchange announced on the 4th that it had approved the preliminary examination of SK Bioscience’s listing. SK Bioscience requested a preliminary review in December of last year, and it exceeded the threshold of the exchange in two months. In the near future, the company plans to submit a stock report containing the schedule of demand forecasting and so on and initiate a public offering.
Internally, it aims to complete listing on the KOSPI in March. It is a fast schedule to begin forecasting demand as early as this month and at the latest in the beginning of next month. SK Biopharmaceuticals, which was listed last year, took about 9 months to finalize the list after requesting for examination.
SK Biopharm is rushing the listing schedule because its corporate value has increased due to the recent COVID-19 vaccine production, and the liquidity of the public offering market is abundant, so it can sufficiently digest the public offering by trillions.
Last 2018 SK chemicals (285130)SK Bioscience, which was spun off from, has grown into a flu vaccine. However, from last year, it has attracted more attention as a corona 19 vaccine. AstraZeneca’s vaccine is consigned to production (CMO), and has signed a contract with NovaVax for consignment development (CDMO). Initially, the value of the company was estimated to be 3 trillion won, but there is a forecast that the ransom will reach 5 trillion won due to vaccine production.
It is also likely that this year’s big companies such as SK IET, Kakao Bank, and LG Energy Solutions are pushing to enter the stock market. It is analyzed as a movement to raise funds in the public offering market prior to listing of large companies.
Meanwhile, it is also of interest that the corporate value of the parent company, SK Chemicals, will be re-evaluated due to the rapid listing schedule of SK Bioscience. In June of last year, when SK Biopharm succeeded in forecasting demand, there is a precedent that the stock price of its parent company, SK, surged. SK Chemicals’ stake in SK Bioscience was 98.04% as of the third quarter of last year. Companies are expected to be re-evaluated based on the value of listed companies in subsidiaries.
/ Reporter Minseok Kim [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >